cellestia-biotech-employee

Dr. Anton Hagenbeek

Clinical Advisory Board Member

Professor Anton Hagenbeek
Professor Anton Hagenbeek received his M.D. degree from the Erasmus University in Rotterdam. He was trained in experimental hematology in the Radiobiological Institute T.N.O. in Rijswijk where he obtained his Ph.D. in 1977 and was, after training in internal medicine / hematology in Rotterdam, a fellow in hematology at U.C.L.A.

He worked as a staff member of the Dr Daniel den Hoed Cancer Center in Rotterdam, Department of Hematology from 1982 until 1997, and was in charge of the autologous and allogeneic stem cell transplantation program there between 1987 and 1994. In 1993 he was appointed Professor of Clinical and Experimental Hemato-Oncology, at the Erasmus University, Rotterdam. His main research interests were in developmental therapeutics for leukemia, focussing on translational research from preclinical animal models and in vitro studies to clinical application. From studies on minimal residual disease and experimental bone marrow transplantation (GVHD-GVL) in the early 1980s, he then moved into immuno-gene therapy of hematological malignancies. To date, his clinical research activities are mainly in the field of (intergroup) studies in non-Hodgkin's lymphomas and Hodgkin lymphomas. He has established two (international) consortia dealing with (1) developing new biological prognostic indices in lymphoma and (2) running first-in-man phase I/II studies with new agents in the lymphomas and chronic lymphocytic leukaemia (CLL). He has (co-)authored 345 papers in peer-reviewed journals. In 1997, he was appointed Professor of Hematology at the University Medical Center Utrecht, The Netherlands. Since 2006 he holds a joined appointment as Professor of Hematology in the Department of Hematology, Academic Medical Center, University of Amsterdam, the Netherlands.